GlaxoSmithKline PLC

Transaction in Own Shares • Nov 19, 2025

National Storage Mechanism | Additional information

RNS Number : 0708I

GSK PLC

19 November 2025

Issued: 19 November 2025, London UK

Transfer of Treasury Shares

 

On 18 November 2025, GSK plc (the "Company") transferred 22,000,000 ordinary shares of 31¼ pence each ("Ordinary Shares") that were held by the Company in treasury ("Treasury Shares") to the Company's Jersey resident trust, the GlaxoSmithKline Employee Trust (the "Jersey Trust"), such Ordinary Shares to be used to satisfy awards granted under the Company's Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received from the trustee of the Jersey Trust, of £17.995 per Ordinary Share, was funded by a loan from GlaxoSmithKline Services Unlimited.

Following the transfer, the Company will hold 234,819,844 Ordinary Shares in treasury and have 4,080,611,266 Ordinary Shares in issue (excluding Treasury Shares).

The total number of voting rights in the Company is 4,080,611,266. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above transfer the percentage of voting rights attributable to the Treasury Shares is 5.75%.

This announcement is made in accordance with the requirements of UK Listing Rule 9.8.2.

Notifications may be sent to [email protected].

V A Whyte

Company Secretary

19 November 2025

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TRSBCBDBXBBDGUI